Opna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN-9840 Showing Significant Tumor Growth Inhibition at the American Association of Cancer Research Annual Meeting by Carolyn Helms | Apr 10, 2024 | Portfolio News
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency by Carolyn Helms | Apr 8, 2024 | Portfolio News
Cohere Health to Further Reduce Administrative Burden for Providers via Epic’s Payer Platform by Carolyn Helms | Apr 3, 2024 | Portfolio News
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome by Carolyn Helms | Apr 2, 2024 | Portfolio News
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis by Carolyn Helms | Mar 13, 2024 | Portfolio News
